Evercore ISI analyst Liisa Bayko maintained a Buy rating on 89bio (ETNB – Research Report) yesterday and set a price target of $33.00. The ...

In a report released on February 28, Brian Abrahams from RBC Capital maintained a Hold rating on 89bio (ETNB – Research Report), with a price ...

Bio Inc (ETNB) has disclosed a new risk, in the Demand category. 89Bio Inc. faces a significant risk if the market ...

Read Our Latest Stock Report on ETNB 89bio Stock Performance ETNB stock opened at $8.88 on Monday. 89bio has a 12 month low of $5.99 and a 12 month high of $16.63. The firm has a 50 day moving ...

Roche RHHBY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking label expansion for its ...

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

“2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of ...

89bio announced a public offering of 21.67 million shares at $8.75 each, aiming for $250 million in gross proceeds. The company's reliance on an upsized public offering may indicate a need for ...

Explore 89bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ETNB. What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals ...

89bio, Inc. (NASDAQ:ETNB – Free Report) – Research analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of 89bio in a research note issued on Sunday, February 2nd.

"2024 marks a tremendous year of execution and progress for 89bio, highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in ...